Literature DB >> 31934555

Active Surveillance of Papillary Thyroid Microcarcinoma: Where Do We Stand?

Min Ji Jeon1, Won Gu Kim1, Ki-Wook Chung2, Jung Hwan Baek3, Won Bae Kim1, Young Kee Shong1.   

Abstract

The recent sharp increase in thyroid cancer incidence is mainly due to increased detection of small papillary thyroid microcarcinoma (PTMC). Due to the indolent nature of the disease, active surveillance (AS) of low-risk PTMCs is suggested as an alternative to immediate surgery to reduce morbidity from surgery. For appropriately selected PTMC patients, AS can be a good management option and surgical intervention can be safely delayed until progression occurs. Many considerations must be taken into account at the time of initiation of AS, including radiological tumor characteristics and clinical characteristics of the patient. A specialized medical team should be assembled to monitor patients during AS with an appropriate follow-up protocol. The fact that some patients require surgery for disease progression after long-term follow-up is a major drawback of the current AS protocol. Evaluation of tumor kinetics by three-dimensional tumor volume measurement during the initial 2-3 years of AS may be helpful for discrimination of PTMCs that need early surgical intervention. In this review, we will discuss the clinical outcomes of surgical intervention and AS, considerations during AS, and unresolved questions about AS.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Active surveillance; Management; Papillary thyroid microcarcinoma

Year:  2019        PMID: 31934555      PMCID: PMC6944910          DOI: 10.1159/000503064

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  49 in total

1.  Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma.

Authors:  Toshihiko Sakai; Iwao Sugitani; Aya Ebina; Osamu Fukuoka; Kazuhisa Toda; Hiroki Mitani; Keiko Yamada
Journal:  Thyroid       Date:  2019-01-08       Impact factor: 6.568

2.  Challenges of Active Surveillance Protocols for Low-Risk Papillary Thyroid Microcarcinoma in the United States.

Authors:  Grace C Haser; R Michael Tuttle; Mark L Urken
Journal:  Thyroid       Date:  2016-04-29       Impact factor: 6.568

3.  Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance.

Authors:  Akira Miyauchi; Takumi Kudo; Yasuhiro Ito; Hitomi Oda; Hisanori Sasai; Takuya Higashiyama; Mitsuhiro Fukushima; Hiroo Masuoka; Minoru Kihara; Akihiro Miya
Journal:  Surgery       Date:  2017-11-02       Impact factor: 3.982

4.  An observational trial for papillary thyroid microcarcinoma in Japanese patients.

Authors:  Yasuhiro Ito; Akira Miyauchi; Hiroyuki Inoue; Mitsuhiro Fukushima; Minoru Kihara; Takuya Higashiyama; Chisato Tomoda; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

5.  Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer.

Authors:  Shriya Venkatesh; Jesse D Pasternak; Toni Beninato; Frederick T Drake; Wouter P Kluijfhout; Chienying Liu; Jessica E Gosnell; Wen T Shen; Orlo H Clark; Quan-Yang Duh; Insoo Suh
Journal:  Surgery       Date:  2016-11-10       Impact factor: 3.982

6.  Detection of Malignancy Among Suspicious Thyroid Nodules <1 cm on Ultrasound with Various Thyroid Image Reporting and Data Systems.

Authors:  Su Min Ha; Jae Kyun Kim; Jung Hwan Baek
Journal:  Thyroid       Date:  2017-09-19       Impact factor: 6.568

7.  Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Carcinoma.

Authors:  Hye-Seon Oh; Hyemi Kwon; Eyun Song; Min Ji Jeon; Tae Yong Kim; Jeong Hyun Lee; Won Bae Kim; Young Kee Shong; Ki-Wook Chung; Jung Hwan Baek; Won Gu Kim
Journal:  Thyroid       Date:  2019-04-08       Impact factor: 6.568

8.  Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients.

Authors:  David Lesnik; Mary Elizabeth Cunnane; David Zurakowski; Gul Ozbilen Acar; Cenk Ecevit; Alasdair Mace; Dipti Kamani; Gregory W Randolph
Journal:  Head Neck       Date:  2013-04-02       Impact factor: 3.147

9.  Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance.

Authors:  Ralph P Tufano; Gary Clayman; Keith S Heller; William B Inabnet; Electron Kebebew; Ashok Shaha; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

10.  Features Predictive of Distant Metastasis in Papillary Thyroid Microcarcinomas.

Authors:  Min Ji Jeon; Won Gu Kim; Yun Mi Choi; Hyemi Kwon; Yu-Mi Lee; Tae-Yon Sung; Jong Ho Yoon; Ki-Wook Chung; Suck Joon Hong; Tae Yong Kim; Young Kee Shong; Dong Eun Song; Won Bae Kim
Journal:  Thyroid       Date:  2015-12-17       Impact factor: 6.568

View more
  15 in total

1.  Five-year follow-up results of thermal ablation for low-risk papillary thyroid microcarcinomas: systematic review and meta-analysis.

Authors:  Se Jin Cho; Sun Mi Baek; Dong Gyu Na; Kang Dae Lee; Young Kee Shong; Jung Hwan Baek
Journal:  Eur Radiol       Date:  2021-03-13       Impact factor: 5.315

2.  Predicting factors of central lymph node metastases in patients with unilateral multifocal papillary thyroid microcarcinoma.

Authors:  Xin Wu; Binglu Li; Chaoji Zheng; Xiaodong He
Journal:  Gland Surg       Date:  2020-06

3.  Development and validation of an individualized nomogram for predicting the high-volume (> 5) central lymph node metastasis in papillary thyroid microcarcinoma.

Authors:  X Wei; Y Min; Y Feng; D He; X Zeng; Y Huang; S Fan; H Chen; J Chen; K Xiang; H Luo; G Yin; D Hu
Journal:  J Endocrinol Invest       Date:  2021-09-07       Impact factor: 4.256

4.  A novel tool for predicting the risk of central lymph node metastasis in patients with papillary thyroid microcarcinoma: a retrospective cohort study.

Authors:  Quan-Lin Guan; Qian-Wen Luo; Shan Gao; Xiao Lv; Si-Jia Li; Bo-Fang Wang; Qing-Qing Han; Yun-Peng Wang; Tao Gong
Journal:  BMC Cancer       Date:  2022-06-02       Impact factor: 4.638

5.  Can Cervical Lymph Node Metastasis Increase the Risk of Distant Metastasis in Papillary Thyroid Carcinoma?

Authors:  Wenlong Wang; Ying Ding; Wei Jiang; Xinying Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-24       Impact factor: 6.055

6.  European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions.

Authors:  Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini
Journal:  Eur Thyroid J       Date:  2021-05-25

7.  Association between preoperative serum TSH and tumor status in patients with papillary thyroid microcarcinoma.

Authors:  Aihong Mao; Ning An; Juan Wang; Yuanyuan Wu; Tao Wang; Zhuoying Wang; Haixia Guan; Jun Wang
Journal:  Endocrine       Date:  2021-03-23       Impact factor: 3.633

Review 8.  Thermal Ablation for Papillary Thyroid Microcarcinoma: How Far We Have Come?

Authors:  Yu Min; Xing Wang; Hang Chen; Jialin Chen; Ke Xiang; Guobing Yin
Journal:  Cancer Manag Res       Date:  2020-12-24       Impact factor: 3.989

9.  Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma.

Authors:  Min Ji Jeon; Yea Eun Kang; Jae Hoon Moon; Dong Jun Lim; Chang Yoon Lee; Yong Sang Lee; Sun Wook Kim; Min-Hee Kim; Bo Hyun Kim; Ho-Cheol Kang; Minho Shong; Sun Wook Cho; Won Bae Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-03-23

10.  The effect of the area proportion of the metastatic lesion within the central metastatic lymph node on response to therapy in papillary thyroid carcinoma.

Authors:  Liuhong Shi; Liang Zhou; Jianbiao Wang; Lei Jin; Yinjiao Lei; Lian Xia; Lei Xie
Journal:  Oncol Lett       Date:  2021-02-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.